Impact Factor 3.831

Frontiers journals are at the top of citation and impact metrics

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2018.01329

Targeted delivery of bioactive molecules for vascular intervention and tissue engineering

Hannah A. Strobel1, Elisabet I. Qendro2, Eben Alsberg3 and  Marsha W. Rolle1*
  • 1Worcester Polytechnic Institute, United States
  • 2University of Massachusetts Medical School, United States
  • 3Case Western Reserve University, United States

Cardiovascular diseases are the leading cause of death in the United States. Treatment often requires surgical interventions to re-open occluded vessels, bypass severe occlusions, or stabilize aneurysms. Despite the short-term success of such interventions, many ultimately fail due to thrombosis or restenosis (following stent placement), or incomplete healing (such as after aneurysm coil placement). Bioactive molecules capable of modulating host tissue responses and preventing these complications have been identified, but systemic delivery is often harmful or ineffective. This review discusses the use of localized bioactive molecule delivery methods to enhance the long-term success of vascular interventions, such as drug-eluting stents and aneurysm coils, as well as nanoparticles for targeted molecule delivery. Vascular grafts in particular have poor patency in small diameter, high flow applications, such as coronary artery bypass grafting (CABG). Grafts fabricated from a variety of approaches may benefit from bioactive molecule incorporation to improve patency. Tissue engineering is an especially promising approach for vascular graft fabrication that may be conducive to incorporation of drugs or growth factors. Overall, localized and targeted delivery of bioactive molecules has shown promise for improving the outcomes of vascular interventions, with technologies such as drug-eluting stents showing excellent clinical success. However, many targeted vascular drug delivery systems have yet to reach the clinic. There is still a need to better optimize bioactive molecule release kinetics and identify synergistic biomolecule combinations before the clinical impact of these technologies can be realized.

Keywords: Drug delivery, Vascular tissue engineering, Vascular graft, Vascular repair, Drug eluting stent, nanoparticle, Aneurysm

Received: 15 Mar 2018; Accepted: 29 Oct 2018.

Edited by:

Chris A. Bashur, Florida Institute of Technology, United States

Reviewed by:

Blanka Sharma, University of Florida, United States
Hui Li, University of California, San Francisco, United States  

Copyright: © 2018 Strobel, Qendro, Alsberg and Rolle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Marsha W. Rolle, Worcester Polytechnic Institute, Worcester, United States, mrolle@wpi.edu